Cite
APA Citation
Patel, M., Luke, J., Hamilton, E., Chmielowski, B., Blumenschein, G., Kindler, H., Bahadur, S., Santa-Maria, C., Koucheki, J., Sun, J., Kaul, S., Chen, F., Zhang, X., Muth, J., Kaminker, P., Moore, P., Sumrow, B., & Ulahannan, S. (n.d.). 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. Journal for immunotherapy of cancer, 8, A193. http://access.bl.uk/ark:/81055/vdc_100144719360.0x000009